DocGo
DocGo's revenue fell 47.7% to $322 million in fiscal 2025. Its operating margin was −55.3%, down from 4.7% a year earlier. Free cash flow was $30 million, down 55.0%. It paid out $11 million in dividends and buybacks, 36% of free cash flow. The diluted share count fell 9.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What DocGo does
DocGo provides medical care outside hospitals and clinics, and runs ambulances. Its nurses and other clinicians visit patients at home or at work for tests, vaccines, screenings and checkups, often linked by video to a physician assistant or nurse practitioner. It also offers telehealth services and remote monitoring of people with chronic conditions. Customers include health insurers, hospitals and health systems, city and state governments, and employers, in the United States and the United Kingdom.
DocGo reports two segments that earn revenue. Transportation Services, under the Ambulnz brand, moves patients between hospitals, clinics and dialysis centers, and brought in about 62% of 2025 revenue. Mobile Health Services, the home and workplace care, brought in about 38%. A growing part of that work closes "gaps in care" for insurers' Medicare and Medicaid members, such as missed screenings. DocGo competes with telehealth and in-home care firms such as Teladoc and DispatchHealth, and in ambulances with local operators, fire departments and larger firms such as Global Medical Response.
Government contracts made up about 48% of revenue in 2025, down from about three quarters the year before, as programs serving newly arrived migrants in New York wound down. At the end of 2025 DocGo had nearly 3,600 employees, most of them healthcare workers, and 582 vehicles in service in the United States and 288 in the United Kingdom.
Its biggest risks, as it describes them
- Its heavy reliance on government contracts and a small number of large customers, which can end or shrink.
- Large up-front costs to start work for new clients that it may not recover if relationships don't last.
- Acquisitions that may be hard to integrate or may not bring the benefits it expects.
- Negative press coverage that could hurt its reputation and its ability to win government contracts.
- Value-based payment deals with insurers that tie its pay to patient outcomes and costs.
Income statement
From fiscal 2021 to 2024, earnings per share fell 10.4% a year and net income 5.5% a year, as new shares raised the share count by 15% and diluted each share's earnings. DocGo then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 176 | 157 | 59 | 89 | 51 |
| Debt incl. finance leases | 12 | 10 | 12 | 15 | 17 |
| Net debt (negative means net cash) | −164 | −147 | −48 | −74 | −34 |
| Net debt to EBITDA | −9.2x | −4.5x | −1.5x | −1.7x | — |
| Debt to equity | 0.1x | 0.0x | 0.0x | 0.1x | 0.1x |
| Interest coverage | 250.4x | 185.5x | 60.2x | 13.4x | −104.0x |
| Current ratio | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
| Quick ratio | 4.4x | 2.7x | 2.0x | 2.5x | 2.3x |
Cash flow
Projections
Project DocGo's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What DocGo says to expect
- Full year 2026: revenue
Full-year 2026 revenue is expected to be approximately $300 million, compared to the Company’s prior guidance of $305-$310 million.
- Full year 2026: adjusted EBITDA
Full-year 2026 adjusted EBITDA 2 is expected to be ($17-$22) million, unchanged from last quarter.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought DocGo shares on the open market, and 1 insider sold $15,334.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | Ely D TendlerGeneral Counsel and Secretary, Director | Sold | 16,850 | $0.91 | $15,334 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 6 of 8 | 3 of 8 |
| Rule of 40 | 30.2% | 9.6% | −38.5% |
| Altman Z'' | 4.05 | 5.40 | −4.26 |
| Accruals ratio | 16.1% | −10.6% | −64.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 3 of 8 | 6 of 8 | 3 of 8 |
Compare
Put DocGo side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| DocGo | FY25 | −47.7% | −55.3% | 9.3% | −84.6% | — | 3 | |
| Fulgent Genetics | FY25 | 13.8% | −28.2% | −38.5% | −8.7% | — | 4 | Compare |
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | Compare |
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | Compare |
| Viemed Healthcare | FY25 | 20.5% | 8.5% | 4.4% | 12.4% | −0.0x | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 94 | 319 | 440 | 624 | 617 | 322 |
| Revenue growth | — | 238.7% | 38.2% | 41.7% | −1.2% | −47.7% |
| Gross profit | — | −133 | −83 | — | — | — |
| Research and development | 1 | 3 | 5 | 11 | 12 | 14 |
| Operating income | −15 | 15 | 22 | 15 | 29 | −178 |
| Net income | −15 | 24 | 35 | 7 | 20 | −182 |
| Diluted EPS (US$) | −0.25 | 0.25 | 0.34 | 0.06 | 0.18 | −1.84 |
| Diluted shares (millions) | 58 | 95 | 103 | 106 | 109 | 99 |
| Cash flow | ||||||
| Cash from operations | −11 | −2 | 29 | −64 | 70 | 34 |
| Capital expenditure | 4 | 5 | 3 | 7 | 4 | 4 |
| Free cash flow | −15 | −7 | 26 | −72 | 66 | 30 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 4 | 0 | 14 | 11 |
| Acquisitions | 0 | 1 | 33 | 20 | 0 | 16 |
| Stock-based compensation | — | 1 | 8 | 21 | 14 | 17 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 32 | 176 | 157 | 59 | 89 | 51 |
| Debt incl. finance leases | 8 | 12 | 10 | 12 | 15 | 17 |
| Total assets | 100 | 310 | 393 | 490 | 456 | 217 |
| Total liabilities | 33 | 82 | 114 | 185 | 140 | 91 |
| Shareholders' equity | 55 | 220 | 273 | 301 | 321 | 144 |
| Margins and ratios | ||||||
| Gross margin | — | −41.7% | −18.9% | — | — | — |
| Operating margin | −15.7% | 4.8% | 5.0% | 2.4% | 4.7% | −55.3% |
| Net margin | −15.7% | 7.5% | 7.8% | 1.1% | 3.2% | −56.6% |
| Free cash flow margin | −16.0% | −2.1% | 5.8% | −11.5% | 10.8% | 9.3% |
| Rule of 40 (growth + FCF margin) | — | 236.6% | 44.0% | 30.2% | 9.6% | −38.5% |
| Return on capital | — | 28.2% | 22.3% | 4.8% | 5.8% | −84.6% |
| Return on equity | — | 17.3% | 14.0% | 2.4% | 6.4% | −78.5% |
| Return on assets | — | 11.6% | 9.8% | 1.6% | 4.2% | −54.2% |
| Net debt to EBITDA | — | −9.2x | −4.5x | −1.5x | −1.7x | — |